@sanofi

An R&D driven, AI-powered biopharma company committed to improving lives and delivering compelling growth. Terms for interactions: https://xitter.cf/t.co/mXmuqtkJaU

 Paris
sanofi.com
Joined April 2009
  • Tweets7.4K
  • Following214
  • Followers146K
3.8KMedia
#NEWS: Positive phase 2b long-term data in ulcerative colitis and Crohn's disease, shared at UEG Week. Read more: sanofi.com/en/media-room/pre… @Teva #UEGWeek2026
Positive phase 2b long-term data in ulcerative colitis and Crohn's disease

ALT Positive phase 2b long-term data in ulcerative colitis and Crohn's disease

1
1
13
1,422
NEWS: We’ve officially started construction on our new state-of-the-art insulin production facility. It will strengthen our ability to reliably supply insulin to millions of people living with #diabetes in Europe and worldwide. Read more here: spkl.io/60117XjmU
Diabetes : Landmark investment underscores long-term commitment to people living with diabetes

ALT Diabetes : Landmark investment underscores long-term commitment to people living with diabetes

1
5
903
We're proud to announce our major partnership with @LeTour de France and @LeTourFemmes as the official sponsor of the white jersey for the best young rider. For both men's and women's categories, the white jersey represents progress, a value at the heart of Sanofi's quest for innovation. The #RaceForHealth Is On! 🚴‍♂️🚴‍♀️ #TDF2027 #SanofiTDF #TourDeFrance
1
3
3
38
15,262
See you on the most iconic roads. The #RaceForHealth Is On
2
5
912
#NEWS: We’ve announced an expansion of our global Alliance with @Regeneron to add multiple next-generation, long-acting antibodies to our joint immunology portfolio. Read more here: spkl.io/60177pWkN
Sanofi and Regeneron expand global Alliance with multiple next-generation antibodies\n

ALT Sanofi and Regeneron expand global Alliance with multiple next-generation antibodies\n

3
3
23
2,869
Our Q2 2026 results are now available. Read the full press release for detailed insights: spkl.io/60197KQtR #SanofiResults $SAN $SNY
9
6
1
14
4,052
#NEWS: Update on our phase 3 program in moderate-to-severe #AtopicDermatitis. Learn more ⬇️ spkl.io/60127JNVK
News update Immunology Update on our phase 3 program in moderate-to-severe atopic dermatitis

ALT News update Immunology Update on our phase 3 program in moderate-to-severe atopic dermatitis

2
4
9
2,719
#NEWS: Our phase 3 results show our medicine met its primary and secondary endpoints in treatment-naïve infants with infantile-onset Pompe disease (IOPD). Read more: sanofi.com/en/media-room/pre…
Our phase 3 study evaluating our treatment in IOPD has met all primary and secondary endpoints

ALT Our phase 3 study evaluating our treatment in IOPD has met all primary and secondary endpoints

5
2
15
4,131
#NEWS: The Japan Ministry of Health, Labour and Welfare has approved the first oral, reversible BTK inhibitor to treat adults with immune thrombocytopenia (ITP) who are refractory to other treatments. Read more ⬇️: sanofi.com/en/media-room/pre…
First BTK inhibitor to treat immune thrombocytopenia approved

ALT First BTK inhibitor to treat immune thrombocytopenia approved

1
5
1
9
2,414
#NEWS: The @EU_Commission has approved our medicine for the treatment of certain people with secondary progressive #MultipleSclerosis , reinforcing our commitment to advancing scientific innovation that address unmet patient needs. Learn more ⬇️ sanofi.com/en/media-room/pre…
Our medicine for secondary progressive multiple sclerosis is now approved in the EU

ALT Our medicine for secondary progressive multiple sclerosis is now approved in the EU

4
13
2,543
Sanofi appoints Paulo Fontoura as Global Head of R&D Pharma, starting September 1, 2026. With 25+ years in pharmaceutical innovation, he brings a track record of 60+ new molecular entities and 20+ FDA/EMA approvals. Read more: sanofi.com/en/media-room/pre… #Sanofi
6
9
1,822
We're chasing the miracles of science to improve people's lives. Last week, the world saw exactly how. 2026 marked our 8th consecutive year at #VivaTech, and we came to show, not tell, with operational AI delivering real impact for patients, today. Learn more: spkl.io/60157EwPB
4
1
11
2,217
Sanofi retweeted
VivaTech
@VivaTechJun 19
From R&D to workflow, AI accelerating evidence. Emmanuel Frenehard, EVP CDO @Sanofi, discusses at #VivaTech what it takes to make healthcare data AI-ready in regulated industries. Scaled AI, accelerated impact.
6
10
1,284
The Ministry of Health, Labour and Welfare in Japan has approved our subcutaneous therapy in combination with approved standard-of-care regimens for the treatment of multiple myeloma. Read the full announcement here: sanofi.com/en/media-room/pre…
Our subcutaneous medicine for patients with multiple myeloma is now approved by the Ministry of Health, Labour and Welfare in Japan

ALT Our subcutaneous medicine for patients with multiple myeloma is now approved by the Ministry of Health, Labour and Welfare in Japan

5
1
14
1,888
What a start at #VivaTech! Visit us at Booth 1D01 through June 20 to experience how we’re reinventing AI across the value chain. Learn more: sanofi.com/en/magazine/ai-in… #Sanofi @VivaTech
2
5
1,006
We’re back at #VivaTech 2026, and we’re raising the bar on what AI can do for global health. Visit us June 17 – 20 at Booth 1D01 to see how our teams are accelerating breakthroughs across everything from research and development to manufacturing and supply, driving faster, smarter impact for patients.
2
6
1,065
The @US_FDA granted accelerated approval for a treatment for #Type1Diabetes. Learn more: spkl.io/60117DB2R
Breaking News FDA grants accelerated approval to a T1D treatment is centered on a white circle with a blurred purple cellular background. A black 'S' logo with a purple dot is at the bottom.

ALT Breaking News FDA grants accelerated approval to a T1D treatment is centered on a white circle with a blurred purple cellular background. A black 'S' logo with a purple dot is at the bottom.

2
15
1,322
#NEWS: Update on our phase 3 clinical study in chronic inflammatory demyelinating polyneuropathy (CIDP). Learn more ⬇️ sanofi.com/en/media-room/pre…
Update on our phase 3 clinical study MOBILIZE for our investigational treatment in chronic inflammatory demyelinating polyneuropathy (CIDP)

ALT Update on our phase 3 clinical study MOBILIZE for our investigational treatment in chronic inflammatory demyelinating polyneuropathy (CIDP)

1
2
3
1,175
With the approval from the @EU_Commission, our subcutaneous multiple myeloma (MM) therapy is now authorized across all existing IV indications for MM in the EU. Read more: sanofi.com/en/media-room/pre…
Our subcutaneous medicine for patients with multiple myeloma is now approved by the European Commission

ALT Our subcutaneous medicine for patients with multiple myeloma is now approved by the European Commission

4
12
1,417
Sanofi retweeted
VivaTech
@VivaTechMay 29
From discovery to delivery, @Sanofi is using #AI to make a real impact🚀 At #VivaTech 2026, see how Sanofi uses AI to deliver faster for patients across R&D, manufacturing & supply & more. Plus, Sanofi & partners will share how AI & quantum tools are driving next‑gen innovation.
4
7
1,404
Load more